Registry study for hemolytic disease in pregnancy
Part of Blood & lymphatic, Genetic & congenital, Women’s health & pregnancy clinical trials.
This study tracks pregnancies affected by hemolytic disease of the fetus and newborn (HDFN). It collects information to better understand the condition and improve care. You may join if you are pregnant with a history of a prior affected pregnancy and have a current antibody that could harm your baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are pregnant and less than 24 weeks along (by ultrasound).
- You had a previous pregnancy affected by hemolytic disease (for example, fetal anemia, needed a blood transfusion before birth, or the baby needed a transfusion or treatment after birth).
- You have a specific antibody in your blood during this pregnancy that can cause hemolytic disease.
- Your baby is shown to have the matching antigen (confirmed by DNA test, amniocentesis, or because the father has it).
- You or your legal representative agree to share your medical records and your baby's records for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests nipocalimab (an antibody medicine) to help prevent severe blood breakdown in a baby when a parent has certain blood antibodies. It enrolls people who previously had severe hemolytic disease in a past pregnancy and who are currently early in pregnancy with the same risk antibodies.
This study measures a protein (S100B) in cord blood from babies who had or did not need a blood transfusion in the womb for hemolytic disease. It looks for possible markers of brain health.
This study tests a new DNA-based method to determine a baby's blood type before birth, which helps doctors manage pregnancies at risk for hemolytic disease of the fetus and newborn (HDFN). It aims to improve care for mothers with blood type incompatibility.
This study tests a new method to measure how much fetal blood leaks into the mother's bloodstream, which can cause severe jaundice in newborns. It may help doctors diagnose hemolytic disease of the newborn earlier and more accurately.
This study looks at two substances in the blood from the umbilical cord (IL-6 and lactate) to see if they can help doctors understand how well a newborn is doing after birth.
This study follows pregnant people who carry a severe hemophilia A gene and their babies after birth. It looks at how hemophilia A is passed down and how it affects families, with the goal of improving understanding and care.
Hear when a new Hemolytic Disease of the Fetus and Newborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.